Toward precision medicine in primary biliary cholangitis

Dig Liver Dis. 2016 Aug;48(8):843-50. doi: 10.1016/j.dld.2016.05.023. Epub 2016 Jun 3.

Abstract

Primary biliary cholangitis is a chronic, cholestatic liver disease characterized by a heterogeneous presentation, symptomatology, disease progression and response to therapy. In contrast, clinical management and treatment of PBC is homogeneous with a 'one size fits all' approach. The evolving research landscape, with the emergence of the -omics field and the availability of large patient cohorts are creating a unique opportunity of translational epidemiology. Furthermore, several novel disease and symptom-modifying agents for PBC are currently in development. The time is therefore ripe for precision medicine in PBC. In this manuscript we describe the concept of precision medicine; review current approaches to risk-stratification in PBC, and speculate how precision medicine in PBC might develop in the near future.

Keywords: Precision medicine; Primary biliary cholangitis; Risk-stratification.

Publication types

  • Review

MeSH terms

  • Carcinoma, Hepatocellular / etiology
  • Carcinoma, Hepatocellular / pathology
  • Cholagogues and Choleretics / therapeutic use*
  • Cholangitis / diagnosis
  • Cholangitis / drug therapy*
  • Clinical Trials as Topic
  • Disease Progression
  • Elasticity Imaging Techniques
  • Humans
  • Liver Cirrhosis, Biliary / diagnosis
  • Liver Cirrhosis, Biliary / drug therapy*
  • Liver Neoplasms / etiology
  • Liver Neoplasms / pathology
  • Precision Medicine / trends*
  • Ursodeoxycholic Acid / therapeutic use*

Substances

  • Cholagogues and Choleretics
  • Ursodeoxycholic Acid